Xcout Intel
Adcendo
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Subscribe to see Adcendo’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Adcendo at a glance
Adcendo is a biotechnology company headquartered in Denmark. It has raised at least $261M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $75M in April 2026. Xcout tracks 15 named people at Adcendo, including Michael Pehl (Chief Executive Officer).
Adcendo leadership
- Michael PehlChief Executive Officer
- Fang Z. NiChief Financial Officer
- Pernille HemmingsenChief Technology Officer
- Dominik MumbergChief Scientific Officer
- Lone H. OttesenChief Medical Officer
- James WangVP, Head of Business Development
9 more named people on record for Adcendo, with roles, board committees and tenure — see the full roster →
Adcendo funding rounds
At least $261M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | 13 named | |
| Series B | $135M | 13 named | |
| — | $51M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Adcendo competitors
A few of Adcendo's closest competitors — see the full list of competitors and alternatives →
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Centrose LLC is a biotechnology company that develops a next-generation antibody-drug conjugate platform known as Extracellular Drug Conjugates (EDCs). These precision medicines target the cell surfaceome by binding multiple extracellular proteins simultaneously without cell internalization or drug release, aiming to create safer and more potent treatments for cancer and drug-resistant tumors.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Get Adcendo's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Adcendo in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access